Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Chambers

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Translational Medicine|November 9, 2006
A novel assay for analysis of the regulation of the function of human osteoclastsBarrie Kirstein, Urszula Grabowska, Bertil Samuelsson, et al.
Bone|October 27, 2007
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclastsKaren Fuller, Kevin M Lawrence, Jade L Ross, et al.
Bone|January 19, 2021
Erratum to 'Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts'Karen Fuller, Kevin M Lawrence, Jade L Ross, et al.
Bone|January 26, 2010
The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin KKaren Fuller, Erik Lindstrom, Michael Edlund, et al.
The Journal of Clinical Investigation|September 17, 2003
A crucial role for thiol antioxidants in estrogen-deficiency bone lossJenny M Lean, Julie T Davies, Karen Fuller, et al.
The Journal of Endocrinology|November 16, 2011
Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channelCharlotte E Combs, Karen Fuller, Hashethra Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580James G Conway, Brad McDonald, Janet Parham, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Translational Medicine|November 9, 2006
A novel assay for analysis of the regulation of the function of human osteoclastsBarrie Kirstein, Urszula Grabowska, Bertil Samuelsson, et al.
Bone|October 27, 2007
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclastsKaren Fuller, Kevin M Lawrence, Jade L Ross, et al.
Bone|January 19, 2021
Erratum to 'Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts'Karen Fuller, Kevin M Lawrence, Jade L Ross, et al.
Bone|January 26, 2010
The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin KKaren Fuller, Erik Lindstrom, Michael Edlund, et al.
The Journal of Clinical Investigation|September 17, 2003
A crucial role for thiol antioxidants in estrogen-deficiency bone lossJenny M Lean, Julie T Davies, Karen Fuller, et al.
The Journal of Endocrinology|November 16, 2011
Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channelCharlotte E Combs, Karen Fuller, Hashethra Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580James G Conway, Brad McDonald, Janet Parham, et al.
Pageof 2